Armistice Capital’s Regeneron Pharmaceuticals REGN Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $27.9M | Sell |
36,126
-47,874
| -57% | -$36.7M | 0.5% | 35 |
|
|
2025
Q4 | $64.8M | Sell |
84,000
-41,206
| -33% | -$28M | 0.77% | 18 |
|
|
2025
Q3 | $70.4M | Buy |
125,206
+25,174
| +25% | +$14.2M | 1.04% | 10 |
|
|
2025
Q2 | $52.5M | Sell |
100,032
-14,041
| -12% | -$7.84M | 0.91% | 11 |
|
|
2025
Q1 | $72.3M | Buy |
114,073
+86,028
| +307% | +$59.2M | 1.08% | 12 |
|
|
2024
Q4 | $20M | Buy |
28,045
+8,013
| +40% | +$6.72M | 0.27% | 74 |
|
|
2024
Q3 | $21.1M | Buy |
20,032
+7,968
| +66% | +$8.87M | 0.34% | 55 |
|
|
2024
Q2 | $12.7M | Sell |
12,064
-10,923
| -48% | -$10.6M | 0.16% | 85 |
|
|
2024
Q1 | $22.1M | Sell |
22,987
-37,013
| -62% | -$35.2M | 0.29% | 60 |
|
|
2023
Q4 | $52.7M | Sell |
60,000
-14,998
| -20% | -$12.4M | 0.72% | 25 |
|
|
2023
Q3 | $61.7M | Sell |
74,998
-49,002
| -40% | -$38.5M | 0.95% | 15 |
|
|
2023
Q2 | $89.1M | Buy |
124,000
+72,000
| +138% | +$55.5M | 1.29% | 10 |
|
|
2023
Q1 | $42.7M | Sell |
52,000
-58,000
| -53% | -$43.7M | 0.62% | 39 |
|
|
2022
Q4 | $79.4M | Sell |
110,000
-26,000
| -19% | -$19.2M | 1.38% | 16 |
|
|
2022
Q3 | $93.7M | Sell |
136,000
-52,000
| -28% | -$32.7M | 1.63% | 13 |
|
|
2022
Q2 | $111K | Buy |
188,000
+104,000
| +124% | +$67.6M | 1.94% | 9 |
|
|
2022
Q1 | $58.7M | Sell |
84,000
-32,000
| -28% | -$20.2M | 1.13% | 27 |
|
|
2021
Q4 | $73.3M | Buy |
116,000
+16,000
| +16% | +$9.84M | 1.2% | 19 |
|
|
2021
Q3 | $60.5M | Sell |
100,000
-56,000
| -36% | -$34.8M | 1.03% | 20 |
|
|
2021
Q2 | $87.1M | Sell |
156,000
-19,000
| -11% | -$9.63M | 1.56% | 13 |
|
|
2021
Q1 | $82.8M | Buy |
175,000
+43,000
| +33% | +$20.9M | 1.9% | 9 |
|
|
2020
Q4 | $63.8M | Buy |
132,000
+48,000
| +57% | +$25.9M | 2.17% | 8 |
|
|
2020
Q3 | $47M | Buy |
84,000
+16,000
| +24% | +$9.7M | 1.71% | 13 |
|
|
2020
Q2 | $42.4M | Buy |
68,000
+4,000
| +6% | +$2.27M | 1.86% | 15 |
|
|
2020
Q1 | $31.3M | Sell |
64,000
-36,000
| -36% | -$14.8M | 1.93% | 14 |
|
|
2019
Q4 | $37.5M | Sell |
100,000
-48,000
| -32% | -$16.1M | 2.17% | 9 |
|
|
2019
Q3 | $41.1M | Buy |
148,000
+24,000
| +19% | +$7.1M | 2.72% | 9 |
|
|
2019
Q2 | $38.8M | Buy |
+124,000
| New | +$41.3M | 2.45% | 9 |
|
|
2019
Q1 | – | Sell |
-70,000
| Closed | -$26.1M | – | 83 |
|
|
2018
Q4 | $26.1M | Sell |
70,000
-5,000
| -7% | -$1.83M | 1.98% | 15 |
|
|
2018
Q3 | $30.3M | Sell |
75,000
-53,000
| -41% | -$20.2M | 1.82% | 23 |
|
|
2018
Q2 | $44.2M | Buy |
128,000
+20,000
| +19% | +$6.26M | 2.88% | 5 |
|
|
2018
Q1 | $37.2M | Buy |
+108,000
| New | +$37.6M | 2.84% | 7 |
|
|
2017
Q4 | – | Sell |
-50,000
| Closed | -$22.4M | – | 76 |
|
|
2017
Q3 | $22.4M | Buy |
50,000
+6,000
| +14% | +$2.86M | 2.63% | 8 |
|
|
2017
Q2 | $21.6M | Buy |
44,000
+4,000
| +10% | +$1.75M | 2.75% | 8 |
|
|
2017
Q1 | $15.5M | Buy |
+40,000
| New | +$14.8M | 3.2% | 7 |
|
Other funds holding REGN
VCM
N
Armistice Capital's REGN Position: Q1 2026 in Review
Armistice Capital reduced its Regeneron Pharmaceuticals (REGN) stake by 57% in Q1 2026, selling an estimated $36.7M and leaving 36,126 shares worth $27.9M. The position accounts for 0.5% of the portfolio, ranked #35.
Armistice Capital first reported a position in REGN in Q1 2017 and has held it in 35 quarters since. The position peaked at $93.7M in Q3 2022. 1,392 funds tracked by Wall St. Rank hold REGN as of Q1 2026.
- Armistice Capital held 36,126 shares of Regeneron Pharmaceuticals worth $27.9M as of Q1 2026.
- Armistice Capital sold 47,874 Regeneron Pharmaceuticals shares in Q1 2026, an estimated $36.7M.
- Regeneron Pharmaceuticals made up 0.5% of Armistice Capital's portfolio in Q1 2026, its #35 holding.
- Armistice Capital first reported a position in Regeneron Pharmaceuticals in Q1 2017 and has held it in 35 quarters since.
- Armistice Capital's Regeneron Pharmaceuticals position peaked at $93.7M in Q3 2022.
- 1,392 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q1 2026.
Based on Armistice Capital's 13F filing for Q1 2026, filed 15 May 2026.